Home

Welcome to BEAT-PC Lab

BEAT-PC Lab (Bidirectional Signaling and Transdifferentiation in Pancreatic cancer) uses different experimental models of pancreatic cancer to investigate the determinants of malignant progression with the ultimate goal to identify new diagnostic and therapeutic approaches. Our functional studies rely on the use of mouse and human organoid cultures, which enable the growth of both neoplastic and non-neoplastic cells. The lab has generated a large array of patient-derived organoids to interrogate efficiency of different therapies and to study fundamental biological questions. Our current projects focus on the identification and characterization of signaling pathways involved in tumor-stoma crosstalk and in the evolution of the disease with a focus on mechanisms of transdifferentiation and cell plasticity. The lab is led by Professor Vincenzo Corbo and it’s part of different international consortia, including the EU-funded project PRECODE and the NCI-sponsored Human Cancer Model Initiative.

See also

Research

People

Publications

Selected Publications

  • D’Agosto S, Pezzini F, Veghini L, Delfino P, Fiorini C, Temgue Tane GD, Del Curatolo A, Vicentini C, Ferrari G, Pasini D, Andreani S, Lupo F, Fiorini E, Lorenzon G, Lawlor RT, Rusev B, Malinova A, Luchini C, Milella M, Sereni E, Pea A, Bassi C, Bailey P, Scarpa A, Bria E, Corbo V. Loss of FGFR4 promotes the malignant phenotype of PDAC. Oncogene. 2022 Sep;41(38):4371-4384.
  • Malinova A, Veghini L, Real FX, Corbo V. Cell Lineage Infidelity in PDAC Progression and Therapy Resistance. Front Cell Dev Biol. 2021 Dec 2;9:795251.
  • Vicentini C, Calore F, Nigita G, Fadda P, Simbolo M, Sperandio N, et al. Exosomal miRNA signatures of pancreatic lesions. BMC Gastroenterol 2020;20(1):137
  • Fiorini E, Veghini L, Corbo V. Modeling Cell Communication in Cancer With Organoids: Making the Complex Simple. Front Cell Dev Biol 2020;8:166
  • Bazzichetto C, Conciatori F, Luchini C, Simionato F, Santoro R, Vaccaro V, et al. From Genetic Alterations to Tumor Microenvironment: The Ariadne’s String in Pancreatic Cancer. Cells 2020;9(2)
  • Vicentini C, Galuppini F, Corbo V, Fassan M. Current role of non-coding RNAs in the clinical setting. Noncoding RNA Res 2019;4(3):82-5
  • Trovato R, Fiore A, Sartori S, Cane S, Giugno R, Cascione L, et al. Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3. J Immunother Cancer 2019;7(1):255
  • Ponz-Sarvise M, Corbo V, Tiriac H, Engle DD, Frese KK, Oni TE, et al. Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer. Clin Cancer Res 2019;25(22):6742-55
  • Luchini C, Veronese N, Nottegar A, Riva G, Pilati C, Mafficini A, et al. Perineural Invasion is a Strong Prognostic Moderator in Ampulla of Vater Carcinoma: A Meta-analysis. Pancreas 2019;48(1):70-6
  • Filippini D, Agosto S, Delfino P, Simbolo M, Piro G, Rusev B, et al. Immunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease. Sci Rep 2019;9(1):12286
  • Simbolo M, Vicentini C, Ruzzenente A, Brunelli M, Conci S, Fassan M, et al. Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma. Sci Rep 2018;8(1):7119
  • Mafficini A, Amato E, Cataldo I, Rusev BC, Bertoncello L, Corbo V, et al. Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations. Ann Surg 2018;267(1):149-56
  • Senturk S, Shirole NH, Nowak DG, Corbo V, Pal D, Vaughan A, et al. Rapid and tunable method to temporally control gene editing based on conditional Cas9 stabilization. Nat Commun 2017;8:14370
  • Scarpa A, Chang DK, Nones K, Corbo V, Patch AM, Bailey P, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature 2017;543(7643):65-71
  • Humphris JL, Patch AM, Nones K, Bailey PJ, Johns AL, McKay S, et al. Hypermutation In Pancreatic Cancer. Gastroenterology 2017;152(1):68-74 e2
  • Ciuffreda L, Del Curatolo A, Falcone I, Conciatori F, Bazzichetto C, Cognetti F, et al. Lack of growth inhibitory synergism with combined MAPK/PI3K inhibition in preclinical models of pancreatic cancer. Ann Oncol 2017;28(11):2896-8
  • Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 2016;531(7592):47-52
  • Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015;518(7540):495-501
  • Boj SF, Hwang CI, Baker LA, Chio, II, Engle DD, Corbo V, et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 2015;160(1-2):324-38